Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques.
Date
2020-10
Journal Title
Journal ISSN
Volume Title
Repository Usage Stats
views
downloads
Citation Stats
Attention Stats
Abstract
A safe and effective vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may be required to end the coronavirus disease 2019 (COVID-19) pandemic1-8. For global deployment and pandemic control, a vaccine that requires only a single immunization would be optimal. Here we show the immunogenicity and protective efficacy of a single dose of adenovirus serotype 26 (Ad26) vector-based vaccines expressing the SARS-CoV-2 spike (S) protein in non-human primates. Fifty-two rhesus macaques (Macaca mulatta) were immunized with Ad26 vectors that encoded S variants or sham control, and then challenged with SARS-CoV-2 by the intranasal and intratracheal routes9,10. The optimal Ad26 vaccine induced robust neutralizing antibody responses and provided complete or near-complete protection in bronchoalveolar lavage and nasal swabs after SARS-CoV-2 challenge. Titres of vaccine-elicited neutralizing antibodies correlated with protective efficacy, suggesting an immune correlate of protection. These data demonstrate robust single-shot vaccine protection against SARS-CoV-2 in non-human primates. The optimal Ad26 vector-based vaccine for SARS-CoV-2, termed Ad26.COV2.S, is currently being evaluated in clinical trials.
Type
Department
Description
Provenance
Subjects
Citation
Permalink
Published Version (Please cite this version)
Publication Info
Mercado, Noe B, Roland Zahn, Frank Wegmann, Carolin Loos, Abishek Chandrashekar, Jingyou Yu, Jinyan Liu, Lauren Peter, et al. (2020). Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature, 586(7830). pp. 583–588. 10.1038/s41586-020-2607-z Retrieved from https://hdl.handle.net/10161/27267.
This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.
Collections
Scholars@Duke
Roger Keith Reeves
Dr. Reeves obtained his Ph.D. at the University of Alabama-Birmingham studying dendritic cell biology in lentivirus infections, then completed his postdoctoral training in lentivirus vaccinology, natural killer cells, and innate immunity at the New England Primate Research Center, Massachusetts General Hospital, and Harvard Medical School (HMS). He later became faculty at HMS and Beth Israel Deaconess Medical Center through the rank of Associate Professor. Upon being recruited to Duke University in 2021, Dr. Reeves became a tenured Professor in the Department of Surgery and the Department of Pathology and Director in the Duke Center for Human Systems Immunology. He currently serves as Editor-in-Chief of the journal AIDS Research and Human Retroviruses and is the immediate past chair of the NIH HIV Immunopathogenesis and Vaccine Development study section. Dr. Reeves also previously sat on NIH F13 fellowship study sections, has served on the HVTN ESI Advisory board for over a decade, and currently is Director of the Duke Center for AIDS Research Developmental Core, collectively mentoring dozens of trainees at all levels. Dr. Reeves’ research has been continuously supported by NIH for well over 15 years, having served as PI on multiple R and P grants in addition to participating in consortia grants such as the HIV Vaccine Trials Network and BEAT-HIV Delaney Cure Collaboratory. Considered a global expert in natural killer cell biology, his research has provided some of the most detailed characterizations of NK cell responses against viruses, and his team was the first to identify memory and memory-like NK cells in humans and nonhuman primates. With over 100 publications in the field and over 60 as senior author, Dr. Reeves’ group continues to focus on cutting-edge approaches to harness NK cells in the context of vaccines and immunotherapeutics for HIV, CMV, HCV, influenza, SARS-CoV-2, congenital CMV, and cancer.
Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.